Stock Events

Ipsen 

€115.3
56
+€0.2+0.17% Wednesday 15:35

Statistics

Day High
116
Day Low
110.4
52W High
126.7
52W Low
99.7
Volume
79,030
Avg. Volume
63,398
Mkt Cap
9.53B
P/E Ratio
14.4
Dividend Yield
1.05%
Dividend
1.21

Upcoming

Dividends

1.05%Dividend Yield
10Y Growth
1.86%
5Y Growth
3.09%
3Y Growth
2.2%
1Y Growth
1.13%

Earnings

25JulExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
0
1.79
3.57
5.36
Expected EPS
4.600042020528
Actual EPS
4.718498038223999

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IPN.PA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Show more...
CEO
Mr. David Loew
Employees
5325
Country
FR
ISIN
FR0010259150

Listings